Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes
Conditions
Interventions
semaglutide
Dulaglutide
Locations
209
United States
Novo Nordisk Investigational Site
Tuscumbia, Alabama, United States
Novo Nordisk Investigational Site
Chandler, Arizona, United States
Novo Nordisk Investigational Site
Phoenix, Arizona, United States
Novo Nordisk Investigational Site
Phoenix, Arizona, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Buena Park, California, United States
Start Date
January 6, 2016
Primary Completion Date
April 10, 2017
Completion Date
May 19, 2017
Last Updated
October 15, 2019
NCT07224321
NCT01399385
NCT07536516
NCT06513026
NCT07340320
NCT07232537
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions